brains form dementia alzheimer earlier trials believed failed tested patients disease advanced damage irrevocable contrast aducanumab tested patients early evidence disease alzheimer field expressed enthusiasm week paper ongoing study aducanumab results impressive encouraging says rudolph tanzi neurologist harvard university longtime leader alzheimer research fact authors ones level proof anti amyloid therapy way treat prevent alzheimer drug performs larger trials tanzi says expects people 40s 50s starting evidence amyloid buildup clearing amyloid keeping levels low type drug tanzi working develop prevent having alzheimer says james hendrix director global science initiatives alzheimer association praised trial saying impressed design results said study shows